98%
921
2 minutes
20
Transgender individuals are disproportionately affected by HIV in the United States. Given increased risk of HIV among youth, there is a need to understand HIV risk and protective factors among transgender individuals who are 18 years and younger. Patterns of HIV testing, HIV education, and condom use have known associations with HIV outcomes among youth in general, but are understudied among transgender youth. This study assessed these outcomes by developing a series of sex-stratified multivariable logistic regression models using pooled Youth Risk Behavior Survey data. Results indicate female and male transgender youth as well as males who were not sure they were transgender were more likely have tested for HIV compared with their not transgender peers. Male transgender youth were significantly less likely to have received HIV education compared with not transgender males. Females not sure if they were transgender and male transgender youth were significantly less likely to have used condoms compared with, respectively, not transgender female and not transgender male counterparts. In sum, condom use and HIV education both remain lower among transgender individuals relative to their not-transgender peers. This highlights the need for the promotion of culturally appropriate HIV education and HIV prevention supports among transgender youth.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320701 | PMC |
http://dx.doi.org/10.1177/10901981221142238 | DOI Listing |
PLOS Glob Public Health
September 2025
International Training and Education Center for Health, Seattle, Washington, United States of America.
Retention on antiretroviral therapy (ART) is critical for achieving viral load suppression (VLS) among people living with HIV (PLHIV). Retention remains challenging in high-prevalence settings like Malawi. Short messaging service (SMS) interventions, particularly hybrid two-way texting (2wT), show promise in improving ART retention.
View Article and Find Full Text PDFTher Drug Monit
September 2025
Departments of Pharmacology, and.
Background: Fluconazole-tacrolimus interactions occur, but the additional effect of ritonavir is emphasized here, underscoring the need for careful prescription reconciliation in renal transplant recipients living with HIV-AIDS to prevent accidental ritonavir coadministration and inadvertent tacrolimus toxicity. The findings provide valuable insight for therapeutic drug monitoring (TDM) specialists. Patient informed consent was obtained for publication of the anonymized data.
View Article and Find Full Text PDFInfect Dis Ther
September 2025
Department of Nursing, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Introduction: Cognitive frailty (CF), which typically precedes dementia and functional decline, serves as a more robust predictor of adverse health outcomes compared to physical frailty alone, representing a critical challenge in promoting healthy aging among older people living with HIV (PLWH) aged ≥ 50 years. This study aimed to investigate the prevalence of cognitive frailty and identify its associated factors among PLWH aged ≥ 50 years.
Methods: A convenience sample of 344 PLWH ≥ 50 years was recruited from a tertiary Grade A hospital in Zunyi, China.
JHEP Rep
October 2025
HEOR-Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.
Background & Aims: HDV leads to the most severe form of viral hepatitis. It has been estimated to affect 5-13% of people who have chronic HBV worldwide. Evidence of HDV incidence, prevalence, and disease burden in Spain is limited.
View Article and Find Full Text PDFPLoS One
September 2025
Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Dublin, Ireland.
Background: Acute viral respiratory infections (AVRIs) rank among the most common causes of hospitalisation worldwide, imposing significant healthcare burdens and driving the development of pharmacological treatments. However, inconsistent outcome reporting across clinical trials limits evidence synthesis and its translation into clinical practice. A core outcome set (COS) for pharmacological treatments in hospitalised adults with AVRIs is essential to standardise trial outcomes and improve research comparability.
View Article and Find Full Text PDF